Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140-149.
Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012;13:1797-1805.
Chacra AR. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy. Am J Ther. 2014;21:198-210.
DeFronzo R, Fleming GA, Chen K, et al. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65:20-29.
Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39:179-190.
Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-371.
Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
Gruszka A. New insight into the mechanisms of the anti-hyperglycemic action of metformin. Br J Med Med Res. 2015;13(1):1-9. doi:10.9734/BJMMR/2016/23354
Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008;51:1552-1553.
Hur KY, Lee M-S. New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig. 2015;6:600-609.
Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9:e100778.
Campbell IW, Clarke BF, Duncan LJP. A clinical evaluation of a delayed release preparation of metformin. J Int Med Res. 1973;1:551-556.
Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucoselowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39:198-205.
Scheen AJ. Personalising metformin therapy: a clinician's perspective. Lancet Diabetes Endocrinol. 2014;2:442-444.
Bakris GL, Mudaliar S, KimT, et al. Effects of new metformin formulation in stage 3 and 4 CKD: a pilot study. J Am Soc Nephrol. 2014;25:549A.
